Nucleonics - About the company
Nucleonics is an acquired company based in Langhorne (United States), founded in 2001. It operates as a Developing RNAi therapeutics for Hepatitis B and C, using eiRNA technology. Nucleonics has raised $51.9M in funding. The company has 721 active competitors, including 225 funded and 178 that have exited. Its top competitors include companies like Human Longevity, Nanopore and Juno Therapeutics.
Company Details
Developing RNAi therapeutics for Hepatitis B and C, using eiRNA technology. The company focuses on addressing unmet clinical needs in treating chronic viral infections. Their eiRNA technology enables novel therapeutic options that interfere with viral function while providing a more favorable toxicity profile. They engineer drug candidates to be effective against all genotypes, resistant to viral escape mutants, and compatible with existing therapies. The company utilizes a multi-targeted approach with short hairpin RNA molecules to mediate the destruction of viral RNA. They also focus on DNA delivery and manufacturing technology, using proprietary formulations of cationic lipids to deliver RNAi molecules to target cells.
- Website
- www.nucleonicsinc.com
- Email ID
- *****@alnylam.com
Key Metrics
Founded Year
2001
Location
Langhorne, United States
Stage
Acquired
Total Funding
$51.9M in 3 rounds
Latest Funding Round
Investors
Ranked
304th among 721 active competitors
Similar Companies
Exit Details
Acquired by Alnylam (Dec 08, 2008)
Nucleonics's acquisition details
Nucleonics got acquired by Alnylam on Dec 08, 2008.
Click here to take a look at Nucleonics's acquisition in detail
Sign up to download Nucleonics' company profile
Nucleonics's funding and investors
Nucleonics has raised a total funding of $51.9M over 3 rounds. Its first funding round was on Apr 01, 2004. Its latest funding round was a Series B round on Oct 12, 2004 for $*****. 1 investor participated in its latest round. Nucleonics has 8 institutional investors.
Here is the list of recent funding rounds of Nucleonics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 12, 2004 | 1914002 | Series B | 7454231 | 4087026 | 8268271 | 8812664 |
Jun 01, 2004 | 1397552 | Series B | 2989504 | 4359006 | 4108949 | |
Apr 01, 2004 | 1052701 | Series B | 7344924 | 4405612 | 8214130 |
Access funding benchmarks and valuations. Sign up today!View details of Nucleonics's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Nucleonics's Competitors and alternates
Top competitors of Nucleonics include Human Longevity, Nanopore and Juno Therapeutics. Here is the list of Top 10 competitors of Nucleonics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Human Longevity 2013, San Diego (United States), Series B | Provider of precision medicine, preventative health assessments, and longevity care | $409M | 76/100 | |
2nd | Nanopore 2005, Oxford (United Kingdom), Public | Developer of nanopore-based electronic systems for the analysis of single molecules | $1.26B | 75/100 | |
3rd | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
4th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 74/100 | |
5th | Dynavax 1996, Berkeley (United States), Acquired | Developer of products to prevent and treat infectious and inflammatory diseases and cancer | $73.9M | 72/100 | |
6th | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 70/100 | |
7th |  UniQure 1998, Amsterdam (Netherlands), Public | Developer of gene-based therapies for patients with genetic or acquired diseases | $111M | 70/100 | |
8th | Orchard Therapeutics 2015, London (United Kingdom), Acquired | Developer of gene therapies for treating rare diseases | $440M | 70/100 | |
9th | Castle Biosciences 2008, Friendswood (United States), Public | Provider of diagnostic devices for treating cancer | $62M | 70/100 | |
10th | Bluebird Bio 1992, Cambridge (United States), Acquired | Developer of gene therapies for severe genetic and rare diseases | $136M | 70/100 | |
304th | Nucleonics 2001, Langhorne (United States), Acquired | Developing RNAi therapeutics for Hepatitis B and C, using eiRNA technology | $51.9M | 36/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Nucleonics's competitors? Click here to see the top ones
Nucleonics's Investments and acquisitions
Nucleonics has made no investments or acquisitions yet.
Are you a Founder ?
FAQs about Nucleonics
Explore our recently published companies
- Jasminebowden - United Kingdom based, Unfunded company
- Anna Bella Fine Lingerie - Latvia based, 2013 founded, Unfunded company
- Vintrol Lubes - Delhi based, 1997 founded, Unfunded company
- DTSolutionz - Howrah based, 2025 founded, Unfunded company
- BuildMate - Nairobi based, 2025 founded, Unfunded company
- Infobrim - 2021 founded, Seed company
